Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Account Payables (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Change in Account Payables for 11 consecutive years, with -$933000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 293.67% to -$933000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 136.42% year-over-year, with the annual reading at $1.1 million for FY2025, 136.42% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$933000.0 at Cartesian Therapeutics, down from $1.8 million in the prior quarter.
  • The five-year high for Change in Account Payables was $2.8 million in Q4 2023, with the low at -$2.4 million in Q3 2024.
  • Average Change in Account Payables over 5 years is $42300.0, with a median of $51500.0 recorded in 2022.
  • The sharpest move saw Change in Account Payables crashed 4782.14% in 2021, then soared 4050.0% in 2023.
  • Over 5 years, Change in Account Payables stood at -$1.4 million in 2021, then soared by 107.46% to $102000.0 in 2022, then surged by 2643.14% to $2.8 million in 2023, then plummeted by 108.47% to -$237000.0 in 2024, then tumbled by 293.67% to -$933000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$933000.0, $1.8 million, and -$1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.